FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2885366554> ?p ?o ?g. }

• W2885366554 endingPage "178" @default.
• W2885366554 startingPage "169" @default.
• W2885366554 abstract "The present studies were designed to evaluate inhalatory microparticles carrying indomethacin (IN) for potential local (specific and non-specific bronchial inflammatory asthma responses) and systemic treatments (joint inflammation, rheumatoid arthritis and osteoarthritis pain) by optimizing microparticle properties, characterizing their lung deposition, drug release, evaluating cytotoxicity and also pharmacological effect in vitro. The acidic groups of IN were complexed with the cationic groups of the polyelectrolyte polylysine in order to increase the drug water compatibility. The polylysine/indomethacin ratio was fixed and the pH was adjusted in different formulations. Microparticles were obtained by spray drying using a relatively high atomization air flowrate (742 L/min) and a high-performance cyclone in order to optimize the production of microparticles with adequate attributes for inhalatory delivery. The produced microparticles exhibited high process yield and IN loading, volumetric mean diameters smaller than 5 μm and narrow particle size distributions. According to demonstrated aerosolization performance, the powders were suitable for inhalatory indomethacin local and systemic treatments. Emitted fraction was higher than 90%, the MMAD was around 3 μm and the GSD lower than 3. The respirable fraction for particles with aerodynamic diameters smaller than 5 μm was around 29% while for particles with aerodynamic diameters smaller than 3 μm the value was around 17%. The addition of lactose as carrier worsened the aerodynamic performance of the microparticles. The developed powdered systems got wet and dissolved quickly and presented higher release rates respect to pure IN in simulated lung physiological conditions. Furthermore, the assays performed in RAW 264.7 cell line showed that the microparticles exhibited the same anti-inflammatory capability as the pure drug. The developed particles did not affect the RAW 264.7 cell viability. In conclusion, a promising powder formulation for DPIs has been developed to treat, locally and systemically, inflammatory diseases." @default.
• W2885366554 created "2018-08-22" @default.
• W2885366554 creator A5007656211 @default.
• W2885366554 creator A5023590664 @default.
• W2885366554 creator A5053715386 @default.
• W2885366554 creator A5056068339 @default.
• W2885366554 creator A5086703648 @default.
• W2885366554 date "2018-10-01" @default.
• W2885366554 modified "2023-10-17" @default.
• W2885366554 title "Carrier free indomethacin microparticles for dry powder inhalation" @default.
• W2885366554 cites W1590254871 @default.
• W2885366554 cites W1897201563 @default.
• W2885366554 cites W1973551521 @default.
• W2885366554 cites W1976336238 @default.
• W2885366554 cites W1976691526 @default.
• W2885366554 cites W1977900726 @default.
• W2885366554 cites W1983222220 @default.
• W2885366554 cites W1985029869 @default.
• W2885366554 cites W1985713056 @default.
• W2885366554 cites W1988681733 @default.
• W2885366554 cites W1988795901 @default.
• W2885366554 cites W1990792948 @default.
• W2885366554 cites W2002137995 @default.
• W2885366554 cites W2005316212 @default.
• W2885366554 cites W2005720785 @default.
• W2885366554 cites W2019608052 @default.
• W2885366554 cites W2019677635 @default.
• W2885366554 cites W2023471157 @default.
• W2885366554 cites W2023568693 @default.
• W2885366554 cites W2025351758 @default.
• W2885366554 cites W2027342181 @default.
• W2885366554 cites W2028210174 @default.
• W2885366554 cites W2028289491 @default.
• W2885366554 cites W2028690412 @default.
• W2885366554 cites W2031521104 @default.
• W2885366554 cites W2041298199 @default.
• W2885366554 cites W2043885426 @default.
• W2885366554 cites W2044446003 @default.
• W2885366554 cites W2060071364 @default.
• W2885366554 cites W2062996457 @default.
• W2885366554 cites W2063124787 @default.
• W2885366554 cites W2068123612 @default.
• W2885366554 cites W2072373568 @default.
• W2885366554 cites W2072454229 @default.
• W2885366554 cites W2081783802 @default.
• W2885366554 cites W2082988430 @default.
• W2885366554 cites W2085051997 @default.
• W2885366554 cites W2086956954 @default.
• W2885366554 cites W2088261556 @default.
• W2885366554 cites W2088486890 @default.
• W2885366554 cites W2089165733 @default.
• W2885366554 cites W2096422707 @default.
• W2885366554 cites W2099051848 @default.
• W2885366554 cites W2100837269 @default.
• W2885366554 cites W2134294475 @default.
• W2885366554 cites W2163797903 @default.
• W2885366554 cites W2274311149 @default.
• W2885366554 cites W2518077625 @default.
• W2885366554 cites W2521900372 @default.
• W2885366554 cites W2528669073 @default.
• W2885366554 cites W2560362102 @default.
• W2885366554 cites W2600909665 @default.
• W2885366554 cites W4293247451 @default.
• W2885366554 doi "https://doi.org/10.1016/j.ijpharm.2018.07.065" @default.
• W2885366554 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30071308" @default.
• W2885366554 hasPublicationYear "2018" @default.
• W2885366554 type Work @default.
• W2885366554 sameAs 2885366554 @default.
• W2885366554 citedByCount "16" @default.
• W2885366554 countsByYear W28853665542018 @default.
• W2885366554 countsByYear W28853665542019 @default.
• W2885366554 countsByYear W28853665542020 @default.
• W2885366554 countsByYear W28853665542021 @default.
• W2885366554 countsByYear W28853665542022 @default.
• W2885366554 countsByYear W28853665542023 @default.
• W2885366554 crossrefType "journal-article" @default.
• W2885366554 hasAuthorship W2885366554A5007656211 @default.
• W2885366554 hasAuthorship W2885366554A5023590664 @default.
• W2885366554 hasAuthorship W2885366554A5053715386 @default.
• W2885366554 hasAuthorship W2885366554A5056068339 @default.
• W2885366554 hasAuthorship W2885366554A5086703648 @default.
• W2885366554 hasConcept C105702510 @default.
• W2885366554 hasConcept C126322002 @default.
• W2885366554 hasConcept C127413603 @default.
• W2885366554 hasConcept C13245373 @default.
• W2885366554 hasConcept C142724271 @default.
• W2885366554 hasConcept C147789679 @default.
• W2885366554 hasConcept C178790620 @default.
• W2885366554 hasConcept C185592680 @default.
• W2885366554 hasConcept C187530423 @default.
• W2885366554 hasConcept C192562407 @default.
• W2885366554 hasConcept C204787440 @default.
• W2885366554 hasConcept C2776042228 @default.
• W2885366554 hasConcept C2776954882 @default.
• W2885366554 hasConcept C2777419714 @default.
• W2885366554 hasConcept C2777521759 @default.
• W2885366554 hasConcept C2778115740 @default.
• W2885366554 hasConcept C2779587474 @default.

• next